|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||1.8000 - 1.8800|
|52 Week Range||1.5600 - 19.8000|
|Beta (3Y Monthly)||1.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Rexahn has engaged Oppenheimer & Co., Inc. as its financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the company.
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.
ROCKVILLE, Md., Aug. 07, 2019 -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient.
A look at the shareholders of Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) can tell us which group is most powerful...